Prevalence of Obesity and its Effects in Patients With COVID-19: A Systematic Review and Meta-analysis.
Hosp Pharm
; 59(3): 341-348, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38764990
ABSTRACT
Background:
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease worldwide. Obesity has been proven to increase the susceptibility of an individual to infections, but the relationship between obesity and COVID-19 is still unclear. This study aimed to conduct a systematic review and meta-analysis of the prevalence of obesity and its effects in patients with COVID-19.Methods:
Web of Science, PubMed and Embase were searched for English language studies up to May 22, 2020. We used a random or fixed-effects model to calculate pooled prevalence rates and odds ratio (OR) with 95% confidence intervals (CI).Results:
Twelve studies with a total of 14 364 patients met the inclusion criteria. The pooled prevalence of obesity in patients with COVID-19 was 32.0% (95% CI, 26%-38%, P < .001). The prevalence of obesity in ICU COVID-19 patients were 37.0% (95% CI, 29%-46%, P < .001). Comparing between obese and non-obese patients, the meta-analysis showed that obesity was an important risk factor associated with COVID-19 patients needed for ICU care (OR 1.36, 95% CI 1.22-1.52, P < .001).Conclusion:
Obesity was highly prevalent (32.0%) in patients with COVID-19, especially in ICU patients (37.0%), and was an important risk factor for COVID-19 patients needed for ICU care.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Hosp Pharm
Year:
2024
Document type:
Article
Affiliation country:
Canada